Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) insider Rachel Mcminn sold 283 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $58.89, for a total value of $16,665.87. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Rachel Mcminn also recently made the following trade(s):

  • On Monday, July 31st, Rachel Mcminn sold 130 shares of Intercept Pharmaceuticals stock. The stock was sold at an average price of $123.12, for a total value of $16,005.60.

Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) traded up 4.52% on Wednesday, hitting $68.73. The stock had a trading volume of 1,847,081 shares. The firm’s market cap is $1.73 billion. The company’s 50-day moving average price is $94.11 and its 200 day moving average price is $111.08. Intercept Pharmaceuticals, Inc. has a 12-month low of $54.98 and a 12-month high of $156.65.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($3.46) EPS for the quarter, topping the Zacks’ consensus estimate of ($3.62) by $0.16. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. The company had revenue of $30.89 million for the quarter, compared to the consensus estimate of $27.50 million. During the same quarter in the previous year, the business earned ($3.14) EPS. The company’s quarterly revenue was up 459.6% compared to the same quarter last year. On average, equities research analysts forecast that Intercept Pharmaceuticals, Inc. will post ($13.99) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Insider Selling: Intercept Pharmaceuticals, Inc. (ICPT) Insider Sells 283 Shares of Stock” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/04/insider-selling-intercept-pharmaceuticals-inc-icpt-insider-sells-283-shares-of-stock.html.

Several institutional investors and hedge funds have recently bought and sold shares of the company. PNC Financial Services Group Inc. raised its stake in shares of Intercept Pharmaceuticals by 0.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,020 shares of the biopharmaceutical company’s stock worth $229,000 after buying an additional 14 shares in the last quarter. Public Employees Retirement Association of Colorado raised its stake in shares of Intercept Pharmaceuticals by 1.1% in the 2nd quarter. Public Employees Retirement Association of Colorado now owns 4,111 shares of the biopharmaceutical company’s stock worth $498,000 after buying an additional 43 shares in the last quarter. Janney Montgomery Scott LLC raised its stake in shares of Intercept Pharmaceuticals by 1.8% in the 2nd quarter. Janney Montgomery Scott LLC now owns 3,435 shares of the biopharmaceutical company’s stock worth $416,000 after buying an additional 62 shares in the last quarter. WFG Advisors LP raised its stake in shares of Intercept Pharmaceuticals by 16.4% in the 2nd quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 125 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Intercept Pharmaceuticals by 14.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 132 shares in the last quarter. 82.19% of the stock is currently owned by institutional investors.

Several equities research analysts have recently commented on ICPT shares. Laidlaw restated a “hold” rating and set a $119.00 price target (up previously from $115.00) on shares of Intercept Pharmaceuticals in a research note on Tuesday, August 1st. Cowen and Company restated an “outperform” rating and set a $232.00 price target on shares of Intercept Pharmaceuticals in a research note on Thursday, September 14th. BMO Capital Markets upped their price target on Intercept Pharmaceuticals from $218.00 to $221.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 1st. BidaskClub upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 24th. Finally, Cantor Fitzgerald restated an “underweight” rating and set a $69.00 price target on shares of Intercept Pharmaceuticals in a research note on Wednesday, September 13th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $162.88.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Insider Buying and Selling by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.